|
SHARON, Pa., May 9 /PRNewswire-FirstCall/ -- NanoLogix,
Inc., (Pink Sheets: IFEC), a Nanobiotechnology
company engaged in the research, development and
commercialization of technologies for the production of bacteria and disease
testing kits, alternative sources of fuel, cancer therapy and remediation of
toxic materials, announces that preliminary data and results of a study which
confirms laboratory proof-of-concept measurements have shown it possible to
generate hydrogen in high yields via the use and adaptation of its intellectual
property. In this study, the bioreactor produced biogas consisting of 50% hydrogen
by volume, without any trace of methane.
Recently, NanoLogix, Inc. (formerly Infectech, Inc.)
signed a feasibility study with the Department of
Environmental Science and Engineering of Gannon University
in Erie, PA to develop a bioreactor which utilizes
NanoLogix's patented bacterial culturing methods
in order to produce hydrogen inexpensively. Hydrogen
reacts with oxygen to yield significant amounts of
energy, and has the added benefit of not producing
carbon dioxide as a by-product (the reaction between
hydrogen and oxygen simply generates water vapor).
NanoLogix believes they have discovered the most
likely method for low cost production of massive
quantities of hydrogen as an alternate energy source.
NanoLogix has ascertained through its patent counsel
that additional patents will be pending beyond those
already filed.
About NanoLogix
NanoLogix, Inc., formerly known as Infectech, Inc.
( http://www.infectech.com/ ),
is a technology application innovator of biogas products
and services designed to assist in worldwide energy
independence and reduce pollution from renewable,
environmentally-friendly energy sources. NanoLogix
is also engaged in the research and development of
diagnostic test kits designed to be used for the
rapid identification of infectious human diseases.
The Company's patents span the identification and
antibiotic sensitivity testing of 34 disease-producing
bacteria, including M. tuberculosis (TB), Mycobacterium
avium-intracellulare (MAI), pseudomonas, and nocardia.
These bacteria are cited as prominent causes of morbidity
and mortality in patients with cancer, cystic fibrosis,
and AIDS. Additionally, NanoLogix owns a patent for
the nontoxic induction of apoptosis in cancer cells
utilizing hydrophobic hydrocarbons. Apoptosis is
a method for inducing a genetically based induction
of "cell suicide" in cells. The Company's 31 patents
can be viewed by visiting http://www.infectech.com/intellectual_property.php .
About Nanotechnology
The convergence of science, medicine and technology
is on the cusp of yielding extraordinary breakthroughs.
Today, patents that were once designed to identify
bacteria have widespread applications across multiple
markets. At the heart of this convergence is nature.
All things begin and end with the building blocks
of life. NanoLogix's portfolio of 31 patents have
yielded a method vital to the development of biophasic
system devices intended for medical purposes to cultivate
and identify certain pathogenic microorganisms. The
devices contain one or more components that suppress
the growth of certain microorganisms while either
promoting or not affecting the growth of other microorganisms.
The FDA registered devices aid in the diagnosis of
disease caused by the pathogenic microorganisms.
products, a method for low cost hydrogen production,
a genomic cancer therapy and methods for cleaning
up toxic environments using bioremediation.
NanoLogix's
patents have nanotechnology applications in medical
drugs/devices, bio-defense sensors, hydrogen production,
cancer treatment and bioremediation. Nanotechnology
applications include Biochips embedded in small
transportable devices for rapid bacteria identification
of disease causing pathogens, and Bio Micro Electro
Mechanical Systems ("BioMEMS")
for rapid environmental microbial monitoring with
bio-defense implications. Its hydrogen bioreactor
research is designed to assist in worldwide energy
independence and reduce pollution using renewable,
environmentally-friendly energy sources. NanoLogix's
FDA registered diagnostic test kits are designed
to be used for the rapid identification of infectious
human diseases and identify 34 disease-producing
bacteria, including Tuberculosis (TB), Mycobacterium
avium-intracellulare (MAI), Pseudomonas, and Nocardia.
These bacteria are cited as prominent causes of morbidity
and mortality in patients with cancer, cystic fibrosis,
and AIDS, as well as in patients undergoing surgery.
Additionally, NanoLogix owns a patent for the nontoxic
induction of apoptosis in cancer cells utilizing
hydrophobic hydrocarbons. Apoptosis is a method for
inducing a genetically based induction of "cell suicide" in
cells. It therefore serves as the foundation for
cancer therapy. NanoLogix's other patents include
technology designed for use in the bioremediation
of contaminated soil and water.
Source: NanoLogix, Inc.
CONTACT: PR Department, NanoLogix, Inc., +1-724-346-1302
Web site: http://www.infectech.com/
http://www.infectech.com/intellectual_property.php
|
